Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Amendment history:
  • Corrigendum (April 2018)

Expression of concern Free access | 10.1172/JCI98066

iNKT cells require TSC1 for terminal maturation and effector lineage fate decisions

Jinhong Wu, Jialong Yang, Kai Yang, Hongxia Wang, Balachandra Gorentla, Jinwook Shin, Yurong Qiu, Loretta G. Que, W. Michael Foster, Zhenwei Xia, Hongbo Chi, and Xiao-Ping Zhong

Find articles by Wu, J. in: PubMed | Google Scholar

Find articles by Yang, J. in: PubMed | Google Scholar

Find articles by Yang, K. in: PubMed | Google Scholar

Find articles by Wang, H. in: PubMed | Google Scholar

Find articles by Gorentla, B. in: PubMed | Google Scholar

Find articles by Shin, J. in: PubMed | Google Scholar

Find articles by Qiu, Y. in: PubMed | Google Scholar

Find articles by Que, L. in: PubMed | Google Scholar

Find articles by Foster, W. in: PubMed | Google Scholar

Find articles by Xia, Z. in: PubMed | Google Scholar

Find articles by Chi, H. in: PubMed | Google Scholar

Find articles by Zhong, X. in: PubMed | Google Scholar

Published November 1, 2017 - More info

Published in Volume 127, Issue 11 on November 1, 2017
J Clin Invest. 2017;127(11):4216–4216. https://doi.org/10.1172/JCI98066.
Copyright © 2017, American Society for Clinical Investigation
Published November 1, 2017 - Version history
View PDF

Related article:

iNKT cells require TSC1 for terminal maturation and effector lineage fate decisions
Jinhong Wu, … , Hongbo Chi, Xiao-Ping Zhong
Jinhong Wu, … , Hongbo Chi, Xiao-Ping Zhong
Research Article

iNKT cells require TSC1 for terminal maturation and effector lineage fate decisions

  • Text
  • PDF
Abstract

Terminal maturation of invariant NKT (iNKT) cells from stage 2 (CD44+NK1.1–) to stage 3 (CD44+NK1.1+) is accompanied by a functional acquisition of a predominant IFN-γ–producing (iNKT-1) phenotype; however, some cells develop into IL-17–producing iNKT (iNKT-17) cells. iNKT-17 cells are rare and restricted to a CD44+NK1.1– lineage. It is unclear how iNKT terminal maturation is regulated and what factors mediate the predominance of iNKT-1 compared with iNKT-17. The tumor suppressor tuberous sclerosis 1 (TSC1) is an important negative regulator of mTOR signaling, which regulates T cell differentiation, function, and trafficking. Here, we determined that mice lacking TSC1 exhibit a developmental block of iNKT differentiation at stage 2 and skew from a predominantly iNKT-1 population toward a predominantly iNKT-17 population, leading to enhanced airway hypersensitivity. Evaluation of purified iNKT cells revealed that TSC1 promotes T-bet, which regulates iNKT maturation, but downregulates ICOS expression in iNKT cells by inhibiting mTOR complex 1 (mTORC1). Furthermore, mice lacking T-bet exhibited both a terminal maturation defect of iNKT cells and a predominance of iNKT-17 cells, and increased ICOS expression was required for the predominance of iNKT-17 cells in the population of TSC1-deficient iNKT cells. Our data indicate that TSC1-dependent control of mTORC1 is crucial for terminal iNKT maturation and effector lineage decisions, resulting in the predominance of iNKT-1 cells.

Authors

Jinhong Wu, Jialong Yang, Kai Yang, Hongxia Wang, Balachandra Gorentla, Jinwook Shin, Yurong Qiu, Loretta G. Que, W. Michael Foster, Zhenwei Xia, Hongbo Chi, Xiao-Ping Zhong

×

Original citation: J Clin Invest. 2014;124(4):1685–1698. https://doi.org/10.1172/JCI69780

Citation for this expression of concern: J Clin Invest. 2017;127(11):4216. https://doi.org/10.1172/JCI98066

An investigative committee at Duke University recently reported that a research technician in the animal pulmonary physiology laboratory fabricated and/or falsified flexiVent data reported in Figure 3A of this paper. The Editorial Board is issuing this Expression of Concern to alert readers to these problems. The Editors have requested that the experiments in question be repeated by the authors and resubmitted to the Journal. We will inform our readers of the outcome after the data have been evaluated.

Footnotes

See the related article at iNKT cells require TSC1 for terminal maturation and effector lineage fate decisions.

Version history
  • Version 1 (November 1, 2017): Print issue publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts